Cutting Edge Imaging With PET-FAPI for Earlier Pancreatic Cancer Diagnosis (INDIGO-FAPI)
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorInstitut Curie
About this trial
Assessment of the relevance of a new medical imaging test, FAPI PET, which could detect progression or relapse earlier than other tests currently available. Ultimately, it could enable early forms of pancreatic cancer to be detected and used for screening.
In addition to the usual examinations prescribed, FAPI PET scans will be repeated at several points in the treatment process.
All study patients must first have been included in the Homing cohort (NCT 04363983, APHP promotion). Clinical characteristics, judgement criteria and results of biological or imaging examinations carried out as part of this cohort will be shared.
Patient follow-up and participation in the study ends when conventional imaging (CT and MRI) shows disease progression, relapse or death.
Eligibility criteria
Qualifiers
Cyto/histologically proven PDAC
Non-metastatic proven PDAC on recent (< 1 month) CT-scan and MRI
Concomitant enrollment in the HoMING prospective cohort (Sponsor: AP-HP, NCT04363983)
Age > 18 years old
Disqualifiers
Protected adults (guardianship, curatorship or safeguarding justice)
Pregnant or breastfeeding woman
Women of childbearing potential not using one highly effective method of contraception
Trial design
Treatments tested in this trial
- 68Ga-FAPI-46 for PET / CT scan
Treatment groups
35 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov